Glioblastoma — clinical trials in Norway
6 open options
- TRIALPHASE3RECRUITING
Lomustine With and Without Reirradiation for First Progression of Glioblastoma: a Randomized Phase III Study
Lomustine · Reirradiation — 45 sites
- TRIALPHASE3RECRUITING
Lomustine in Addition to Standard of Care in Patients With MGMT Methylated Glioblastoma
Temozolomide · Lomustine — 20 sites
- TRIALNARECRUITING
Feasibility of Aspirate Tissue Monitoring in Neuro-oncological Surgery
Aspirate tissue monitoring · Fluorescence-guided surgery — 3 sites
- TRIALPHASE1 / PHASE2RECRUITING
Bortezomib and Temozolomide in Recurrent Grade-4 Glioma Unmethylated MGMT Promoter (BORTEM-17)
Bortezomib and Temozolomide Phase IB · Bortezomib and Temozolomide Phase II — 2 sites
- TRIALPHASE2RECRUITING
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
BMS-986504 · Daraxonrasib · Nivolumab + Relatlimab FDC — 57 sites
- TRIALPHASE2RECRUITING
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
Plixorafenib — 70 sites
Live from ClinicalTrials.gov, refreshed at most hourly · registry query ↗
Not medical advice. Trial0 is a navigation service, not a medical provider. Nothing here is medical advice or a recommendation to pursue any treatment; eligibility matching is informational, based on published registry criteria, and only the trial site or treating clinician can determine actual eligibility. Decisions belong with the patient and their own doctors.